Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:HPST OTCMKTS:NMHLY NASDAQ:VIRI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHPSTHempstract$0.04-0.5%$0.04$0.00▼$0.04$31.34M1.7850,336 shs2,443 shsNMHLYNMC Health$0.00$0.00$0.00▼$0.18N/A-5.2616,591 shs100 shsVIRIVirios Therapeutics$4.80-0.6%$5.01$0.13▼$1.04$92.44M1.581.05 million shs12,767 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHPSTHempstract0.00%0.00%0.00%+338.10%+1,087.10%NMHLYNMC Health0.00%0.00%0.00%0.00%0.00%VIRIVirios Therapeutics0.00%+0.63%-1.84%+32.96%+1,782.35%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHPSTHempstractN/AN/AN/AN/AN/AN/AN/AN/ANMHLYNMC HealthN/AN/AN/AN/AN/AN/AN/AN/AVIRIVirios TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHPSTHempstract 0.00N/AN/AN/ANMHLYNMC Health 0.00N/AN/AN/AVIRIVirios Therapeutics 2.00Hold$5.004.17% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHPSTHempstractN/AN/AN/AN/AN/AN/ANMHLYNMC HealthN/AN/AN/AN/AN/AN/AVIRIVirios TherapeuticsN/AN/AN/AN/A$0.20 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHPSTHempstractN/AN/A0.00∞N/AN/AN/AN/AN/ANMHLYNMC HealthN/AN/A0.00∞N/AN/AN/AN/AN/AVIRIVirios Therapeutics-$5.30M-$0.27N/AN/AN/AN/A-130.33%-115.00%8/6/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHPSTHempstractN/AN/AN/AN/AN/ANMHLYNMC Health$0.2098,000.00%N/AN/AN/AVIRIVirios TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHPSTHempstractN/AN/AN/ANMHLYNMC HealthN/AN/AN/AVIRIVirios TherapeuticsN/A7.277.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHPSTHempstractN/ANMHLYNMC HealthN/AVIRIVirios Therapeutics9.05%Insider OwnershipCompanyInsider OwnershipHPSTHempstract28.10%NMHLYNMC HealthN/AVIRIVirios Therapeutics12.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHPSTHempstract2851.64 million612.33 millionNot OptionableNMHLYNMC Health17,748N/AN/ANot OptionableVIRIVirios Therapeutics519.26 million16.91 millionOptionableNMHLY, HPST, IDH, and VIRI HeadlinesRecent News About These CompaniesVirios Therapeutics (NASDAQ:VIRI) Stock Price Down 2.9% - Here's What HappenedJune 25, 2025 | marketbeat.comDigital acceptance and commitment therapy for fibromyalgia – Authors' replyJune 13, 2025 | thelancet.comTDogwood Therapeutics Inc (DWTX)March 16, 2025 | investing.comDogwood prices 578,950 shares at $8.26 in registered direct offeringMarch 13, 2025 | markets.businessinsider.comDogwood announces conversion of existing $19.5M in debt to equityMarch 12, 2025 | markets.businessinsider.comDWTX Stock trading resumesFebruary 11, 2025 | markets.businessinsider.comDogwood Therapeutics, Inc. (DWTX)February 2, 2025 | finance.yahoo.comDWTX Stock trading halted, volatility trading pauseJanuary 28, 2025 | markets.businessinsider.comDWTX Stock Hits 52-Week High at $15.74 Amidst Strong Yearly GrowthJanuary 23, 2025 | msn.comDogwood announces first patient dosed in Phase 2b trial on HalneuronJanuary 21, 2025 | markets.businessinsider.comPolluted communities hold their breath as companies struggle with California’s diesel truck banDecember 10, 2024 | apnews.comADogwood Therapeutics faces potential Nasdaq delistingNovember 23, 2024 | uk.investing.comDogwood says low-dose IMC-2 treatment reduces long-COVID fatigueNovember 18, 2024 | markets.businessinsider.comDogwood Study Finds IMC-2 Treatment Reduces Long-COVID Related Fatigue, Sleep DisturbanceNovember 18, 2024 | markets.businessinsider.comInovio Pharmaceuticals (NASDAQ:INO) Stock Quotes, Forecast and News SummaryNovember 16, 2024 | benzinga.comDWTX: Phase 2 Long COVID Results Expected SoonNovember 12, 2024 | msn.comBuy Rating for Dogwood Therapeutics: Strategic Initiatives and Promising Pipeline Drive Analyst ConfidenceNovember 10, 2024 | markets.businessinsider.comDogwood Therapeutics Reports Q3 2024 Financial ResultsNovember 9, 2024 | markets.businessinsider.comDogwood Therapeutics Announces Third Quarter 2024 Financial ResultsNovember 8, 2024 | markets.businessinsider.comDogwood Therapeutics, Inc.: Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementOctober 31, 2024 | finanznachrichten.deDogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementOctober 30, 2024 | finance.yahoo.comMedia Sentiment Over TimeNMHLY, HPST, IDH, and VIRI Company DescriptionsHempstract OTCMKTS:HPST$0.04 0.00 (-0.54%) As of 05/14/2025Hempstract, Inc. produces and sells cannabidiol (CBD) and cannabigerol solutions in the United States. It offers CBD isolate powder and distillate oil. The company was formerly known as Riverdale Oil and Gas Corporation and changed its name to Hempstract, Inc. in November 2020. Hempstract, Inc. is based in Warden, Washington.NMC Health OTCMKTS:NMHLY$0.0002 0.00 (0.00%) As of 07/24/2023NMC Health plc provides healthcare services in the United Arab Emirates, the United Kingdom, Spain, and internationally. The company owns and manages healthcare facilities, including hospitals, medical centers, long term care facilities, day surgery centers, fertility clinics, and home health services providers. The company offers medical services comprising diagnostic, and in and outpatient services, as well as research and medical services in the field of gynecology, obstetrics, and human reproduction; and management services in respect of hospitals, as well as retails pharmaceutical goods. NMC Health plc was founded in 1974 and is based in London, United Kingdom.Virios Therapeutics NASDAQ:VIRI$4.80 -0.03 (-0.62%) As of 07/3/2025Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
